Biofrontera AG (BFAGY)
| Market Cap | 62.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 28.36M |
| EPS (ttm) | 0.57 |
| PE Ratio | 3.89 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 2.20 |
| Day's Range | n/a |
| 52-Week Range | 1.50 - 2.78 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 10.60 (+381.8%) |
| Earnings Date | n/a |
About BFAGY
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its...
Financial Performance
In 2020, Biofrontera AG's revenue was 30.35 million, a decrease of -2.94% compared to the previous year's 31.27 million. Losses were -13.02 million, 77.0% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 5 analysts, the average rating for BFAGY stock is "Buy." The 12-month stock price forecast is 10.6, which is an increase of 381.82% from the latest price.
News
Why Biofrontera Stock Is Surging Today
Biofrontera Inc (NASDAQ: BFRI) shares are trading significantly higher Wednesday after the company announced it received U.S. Food and Drug Administration approval for its cGMP laboratory in Germany. Th...
Biofrontera AG decides to delist ADS from Nasdaq to reduce complexity and costs
Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its America...
Why Are Biofrontera Shares Rising Today?
Biofrontera Inc BFRI has provided an update on the patient recruitment for the Phase 3 study for superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (PDT) combined with BF-RhodoLED ...
What's Going On With Biofrontera Shares Today?
Biofrontera Inc (NASDAQ:BFRI) is trading higher Tuesday on abnormally-high volume. The stock is seeing increased interest across social media platforms.
BFRI Stock Alert: The Social Media Chatter That Has Biofrontera Booming Today
Biofrontera (BFRI) stock is on the move today as traders take to Twitter (TWTR) to discuss the latest news surrounding the company. The post BFRI Stock Alert: The Social Media Chatter That Has Biofronte...
Biofrontera Shares Are Trading Higher After Benchmark Initiates Coverage
Benchmark initiated coverage of Biofrontera Inc (NASDAQ:BFRI) with a Buy rating and $11 price target. The Company specializes in medical dermatology, which recently came public in the U.S. as a carve-o...
Biofrontera Is Promising, But Could Be Limited by Competition and Volatility
BFRI stock could rise on the company's treatment for actinic keratosis, which can lead to skin cancer, but it has hurdles to overcome first. The post Biofrontera Is Promising, But Could Be Limited by Co...
$20 Price Prediction Is Ambitious but Possible for Biofrontera
BFRI stock is an imperfect investment as Biofrontera isn't currently profitable, but a new patent could provide a significant revenue source. The post $20 Price Prediction Is Ambitious but Possible for ...
Why Are Biofrontera Shares Surging Today?
The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Inc (NASDAQ: BFRI) titled "Illumination for Photodynamic Therapy." The patent covers pain-reducing ...
BFRI Stock: The News That Has Biofrontera Shares Bounding Higher Today
Biofrontera (BFRI) stock is getting a boost on Thursday thanks to an update from the United States Patent and Trademark Office. The post BFRI Stock: The News That Has Biofrontera Shares Bounding Higher ...
BFRI Stock: 7 Things to Know About Biofrontera as Shares Rocket on $20 Price Prediction
Biofrontera (BFRI) stock is catching the eyes of investors on Wednesday following a bullish price prediction and new rating. The post BFRI Stock: 7 Things to Know About Biofrontera as Shares Rocket on $...
Biofrontera AG announces mediation results
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours an...
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financ...
Biofrontera AG announces initiation of clinical studies
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that two clinic...
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its fin...
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the appro...
Biofrontera reports preliminary approximate revenues for the month of September 2021
Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminar...
Biofrontera reports preliminary revenue for the month of August 2021
Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported prelimina...
Biofrontera reports financial results for the six months ended June 30, 2021
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financ...
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its fin...
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klin...
Biofrontera Inc. seeks IPO in the USA
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc.
Biofrontera reports preliminary revenue for the month of June 2021
Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminar...
Biofrontera reports preliminary revenue for the month of May 2021
Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminar...
Biofrontera reports Q1 2021 financial results
Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financi...